Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017
Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017
复制标题
DOI：
10.1016/j.annepidem.2018.06.009
复制
发表时间：
2018-12-01
影响因子：
5.6
通讯作者：
Siegler, Aaron J.
中科院分区：
文献类型：
--
作者：
Sullivan, Patrick S.;Giler, Robertino Mera;Siegler, Aaron J.
目的：口服恩曲他滨/富马酸替诺福韦酯（TDF/ FTC）的暴露前预防（PrEP）可将HIV感染风险降低>90%。PrEP使用的流行趋势，占已经停止PrEP的人，增加到2016年，但没有被描述，因为......方法：独特的，TDF/FTC PrEP用户（个人在给定的一年中有>= 1天的填充PrEP处方）在美国（US）的年度流行率估计生成2012-2017从国家处方数据库。使用经验证的算法来区分用于HIV或慢性B型肝炎治疗或暴露后预防的TDF/FTC使用者与PrEP使用者。我们计算了PrEP使用的总体年度流行率以及年龄，性别和地区。我们使用对数转换来计算PrEP使用流行率的估计年度百分比变化（EAPC）。结果：PrEP使用的年度流行率从2012年的33/100，000人口增加到2017年的36.7-从2012年到2017年每年增加56%（EAPC：+56%）。男性使用PrEP的年度流行率比女性增长更快（EAPC：分别为+68%和+5%）。按年龄组划分，PrEP使用的年流行率在25至34奥尔兹中增长最快（EAPC：+61%），在≥ 55奥尔兹中增长最慢（EAPC：+52%），
Purpose: Pre-exposure prophylaxis (PrEP) with oral emtricitibine/tenofovir disoproxil fumarate (TDF/ FTC) reduces the risk of HIV infection by >90% when taken as prescribed. Trends in prevalence of PrEP use, which account for persons who have stopped PrEP, increased through 2016, but have not been described since.Methods: Annual prevalence estimates of unique, TDF/FTC PrEP users (individuals with >= 1 day of a filled PrEP prescription in a given year) in the United States (US) were generated for 2012-2017 from a national prescription database. A validated algorithm was used to distinguish users of TDF/FTC for HIV or chronic Hepatitis B treatment or postexposure prophylaxis from PrEP users. We calculated annual prevalence of PrEP use overall and by age, sex, and region. We used log-transformation to calculate estimated annual percent change (EAPC) in the prevalence of PrEP use.Results: Annual prevalence of PrEP use increased from 33/100,000 population in 2012 to 36.7 in 2017 -a 56% annual increase from 2012 to 2017 (EAPC: +56%). Annual prevalence of PrEP use increased faster among men than among women (EAPC: +68% and +5%, respectively). By age group, annual prevalence of PrEP use increased fastest among 25- to 34-year olds (EAPC: +61%) and slowest among >= 55-year olds (EAPC: +52%) and